Board of Directors
Peter Carlton, CFA

Peter is Managing Director at Oakmont Corporation, a registered investment advisor formed in 1984 to serve as the family office for the founder of Trust Company of the West and now overseeing approximately $2.5b in assets for high networth clients and investors. His key responsibilities at Oakmont include leading the investment team that manages Oakmont's portfolio of private equity investments. Peter also serves as president of The Cypress Funds, an affiliated long/short hedge fund with $400m of assets under management. He also serves on the board of directors of Liberty Oilfield Services, TruthMD LLC, and Balance Therapeutics. He has over eleven years of experience working in the investment management industry.

Peter is a CFA charter holder and a member of the CFA Society of Los Angeles. Peter holds a BA in Economics from the University of Colorado.

Richard Chin, M.D.

Richard is founder and CEO of Kindred Bio (NASDAQ: KIN), a biotech company developing drugs for companion animals. Dr. Chin has extensive expertise in drug development, having overseen over 45 Investigational New Drug (IND) Applications, as well as numerous New Drug Applications (NDAs)/Biologic License Applications (BLAs)/Marketing Authorization Applications (MAAs). The current aggregate sales of products developed and/or approved under Dr. Chin's supervision such as Lucentis, Tysabri, Xolair, and Rituxan (for rheumatoid arthritis) exceed $10 billion per year.

Dr. Chin is also an Associate Professor at the UCSF School of Medicine and has authored several textbooks on clinical trial medicine. Dr. Chin serves on the board of directors for Galena Biopharma (NASDAQ:GALE). Most recently, Dr. Chin was CEO of OneWorld Health (acquired by PATH in 2011), the first U.S. nonprofit pharmaceutical company. OneWorld Health, funded by the Bill and Melinda Gates Foundation, develops affordable drugs for neglected patients in the developing world, and is a leader in synthetic biology. He was also CEO of Oxigene, a NASDAQ-listed biotech company where he was named by BusinessWeek in 2006 as one of the youngest 99 public company CEOs in the United States. Dr. Chin was also Senior Vice President of Global Development at Elan, and Head of Clinical Research for the Biotherapeutics Unit at Genentech where he oversaw half of the products at Genentech.

Dr. Chin is an internist, with an M.D. from Harvard, and also holds the equivalent of a J.D. from Oxford University where he studied as a Rhodes Scholar.

Carl L. Gordon, Ph.D.,CFA

Carl is a founding Partner and Co-Head of Global Private Equity at OrbiMed. He was a senior biotechnology analyst at Mehta and Isaly from 1995 to 1997. He was a Fellow at The Rockefeller University from 1993 to 1995.

Carl received a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology (1993) and a Bachelor of Arts Degree from Harvard College (1987). Carl was included on the Forbes Midas List of top venture capital investors in 2014.

Mike Grey

Mike Grey currently serves as a venture partner at Pappas Ventures and is chairman, chief executive officer and a founder of Reneo Pharmaceuticals, Inc., a private biotechnology company. Previously he founded and was president and chief executive officer at Lumena Pharmaceuticals, Inc., a company developing treatments for pediatric and adult orphan diseases, until its acquisition by Shire plc.

Mike has 40 years of experience in the pharmaceutical and biotechnology industries, and has held senior positions at a number of companies, including president and chief executive officer of Auspex Pharmaceuticals, Inc., president and chief executive officer of SGX Pharmaceuticals, Inc., which was acquired by Eli Lilly in 2008, president and chief executive officer of Trega Biosciences, Inc., which was acquired by Lion Bioscience in 2001, and president of BioChem Therapeutic Inc. For approximately 20 years, Mike served in various roles with Glaxo, Inc. and Glaxo Holdings plc, culminating in his position as vice president, corporate development and head of international licensing.

Mike also serves on the board of directors of BioMarin Pharmaceutical Inc., Horizon Pharma plc, Mirati Therapeutics, Inc., Selventa, Inc. and Ziarco Pharma Ltd. He received a B.Sc. in chemistry from the University of Nottingham in the United Kingdom.

Lyndon Lien, Ph.D.

Lyndon serves as the President and Chief Executive Officer of Balance Therapeutics and provides overall leadership for the company. Previously, Lyndon was Vice President of Corporate Strategy and Alliances at Elan Pharmaceuticals and was responsible for strategic planning and business development. As Director of Technology Planning at ALZA a specialty pharmaceutical company of Johnson & Johnson, he led technology strategy and new product planning teams. He was also a Principal at the venture capital company Coastview Capital and led and supported successful investments in early stage biopharmaceutical and research tool companies. Lyndon started his business career with McKinsey & Company, led project teams as an Engagement Manager and provided counsel to senior executives of leading healthcare companies on business strategy, R&D strategy, operations, new business creation, mergers/acquisitions, and product commercialization.

Lyndon has an A.B. in Biochemical Sciences from Harvard University, an M.B.A. from MIT Sloan School of Management and a Ph.D. in Genetics from Harvard University.

Phyllis Whiteley, Ph.D.

Phyllis Whiteley is a Venture Partner with Mohr Davidow Ventures and the CEO and co-founder of Didimi, Inc. Dr. Whiteley has a passion for personalized medicine and transformative life science innovations. She has more than 25 years of experience across academics, biotech, and pharma in R&D, business, and portfolio management and has significant international experience, having established affiliates in Japan and Europe. Her work in Pharmacology, Immunology, and Inflammation has resulted in multiple new chemical entities and publications.

While an Executive-in-Residence at Mohr Davidow Ventures, Dr. Whiteley provided hands-on leadership in building and creating multiple companies in diagnostics and personalized medicine including On-q-ity and Verinata Health. Dr. Whiteley previously co-founded Anaphore, Inc. with 5AM Ventures. Prior to her work in venture capital, Dr. Whiteley was an Officer and Senior Vice President, Business Development, Licensing, and Alliance Management at Perlegen Sciences, Inc. Before joining Perlegen, she served as Vice President, Strategic Portfolio Management for F. Hoffman La Roche. During her ten years with Roche she held various positions in Business Development based in Basel, Switzerland and R&D leadership positions in the US. Prior to her Roche tenure, Dr. Whiteley held a Senior Research Immunology role with Merck.

Dr. Whiteley is a Global Social Benefit Incubator (GSBI) mentor at Santa Clara University and serves on multiple boards and advisory roles including Didimi, VitaPath Genetics, the Personalized Medicine Coalition (emeritus), Coulter Foundation Business Advisor, and Springboard Enterprises. She received her B.A. in Chemistry and Ph.D. in Pharmacology from Washington University.